- Cardiol Therapeutics (CRDL) appoints Teri Loxam and Chris Waddick to its Board of Directors
- Loxam has over 25 years of experience in the pharmaceutical, life sciences, and entertainment industries
- Waddick has over thirty years of experience in financial and executive roles in the biotechnology and energy industries
- Cardiol Therapeutics is a clinical-stage life sciences company
- Cardiol Therapeutics Inc. (CRDL) was up 4.32 per cent, trading at C$1.45 per share at 1:20 pm ET
Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.
Loxam has over 25 years of experience in the pharmaceutical, life sciences, and entertainment industries. Her diverse roles included strategy, investor relations, finance, and communications.
Loxam joined Kira Pharmaceuticals in November 2021 as Chief Operating Officer and Chief Financial Officer. In this role, she oversees finance, operations, and strategic functions for the company.
Prior to joining Kira, Loxam served as Chief Financial Officer at SQZ Biotech. She was instrumental in helping the company raise over $200M in private and public funding. This includes taking the company public through an IPO on the NYSE in October 2020.
She has extensive industry experience. She has served in a variety of key roles since the start of her career as a marine biologist. Loxam holds an MBA from the University of California, Irvine, and a Bachelor of Science degree in Biology from the University of Victoria, B.C. Canada.
Waddick has over thirty years of experience in financial and executive roles in the biotechnology and energy industries. He has substantial knowledge of public company management and corporate governance, and in designing, building, and managing financial processes, procedures, and infrastructure.
Waddick has served as Chief Financial Officer and Corporate Secretary of Cardiol since August 16, 2018. He serves as Executive Vice President and Chief Financial Officer for a private Ontario energy company.
Waddick has also spent more than twelve years at Vasogen Inc.. While serving as Chief Financial Officer and Chief Operating Officer, the company grew from start up to an organization employing over 250 employees. Vasogen went public on the TSX and the NASDAQ, reaching a market capitalization of over US$1 billion.
Prior to Vasogen, he was with Magna International Inc. and Union Gas Limited. Waddick is a CPA and earned a business degree from Wilfrid Laurier University and a Master of Business Administration from York University.
Dr. Guillermo Torre, Chairman of Cardiol Therapeutics commented on the appointment.
“We are delighted that Teri and Chris have agreed to join our Board of Directors. Their extensive and diversified experience will be invaluable to our continued growth and success as we advance the development of important new anti-fibrotic and anti-inflammatory therapeutics for the treatment of heart disease.”
Cardiol Therapeutics is a clinical-stage life sciences company. It focuses on the research and clinical development of cannabidiol as an anti-fibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease (“CVD”).
Cardiol Therapeutics Inc. (CRDL) was up 4.32 per cent, trading at C$1.45 per share at 1:20 pm ET.
